Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Inovio Pharmaceuticals Inc (INO) Com NPV

Sell:$8.74 Buy:$8.75 Change: $0.27 (3.00%)
Market closed |  Prices as at close on 16 April 2021 | Switch to live prices |
Sell:$8.74
Buy:$8.75
Change: $0.27 (3.00%)
Market closed |  Prices as at close on 16 April 2021 | Switch to live prices |
Sell:$8.74
Buy:$8.75
Change: $0.27 (3.00%)
Market closed |  Prices as at close on 16 April 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Contact details

Address:
6769 Mesa Ridge Rd
SAN DIEGO
92121-2995
United States
Telephone:
+1 (858) 4103134
Website:
www.inovio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
INO
ISIN:
US45773H2013
Market cap:
$1.84 billion
Shares in issue:
208.31 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Jong Kim
    President, Chief Executive Officer, Director
  • Peter Kies
    Chief Financial Officer
  • Jacqueline Shea
    Chief Operating Officer
  • Laurent Humeau
    Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.